How can the pharmaceutical industry lead the way in data transparency and give more patients the confidence to share their records with researchers?

It has become clear that healthcare professionals don’t want to be sold to. They want to be partners with industry and be treated as such. How can the rep model evolve to stay in line with expectations?

The increasing focus on patient centricity in recent years has ensured pharmaceutical companies are far more in sync with the issues that patients’ face on a day-to-day basis than ever before; however, translating these insights into treatment improvements remains a challenge.

Decline in R&D productivity levels is rapidly becoming one of the biggest challenges for the pharmaceutical industry, but what can it do?

Victoria Elegant, Vice President and Region Head of Medical, Amgen, shares insights on the importance of diversity in delivering innovation, pharma in the JAPAC region and what medical affairs teams across the globe can learn from China.

Perfectly positioned to bridge the gap between R&D and commercial, MA must seize their strategic position within the industry to guide the future of the function.

The regulatory ecosystem of the pharmaceutical industry and people’s decreasing attention spans is proving a complex reality for marketers that has provided an imperative to innovate.

What helps people to stick to their medication regimes, and how can pharma begin to recover their revenue as well as striving for better health outcomes?